Evolv Technologies: Record Revenue, Positive Cash Flow — So Why Is the Stock Down 40%?

Evolv Technologies (NASDAQ: EVLV) just closed a year in which revenue hit a record, operating cash flow turned positive, and contracted backlog topped $326 million — yet the shares sit at a 52-week low of $3.90, down roughly 40% over twelve months while the broader security and protection services industry gained about 44%. If the business is visibly getting better, why is the market pricing it as a broken story? The honest answer is that the market isn't doubting the growth. It's doubting the books. Working out whether that discount is deserved — or overdone — is the central question for anyone looking at EVLV today.

What Evolv actually sells

Evolv makes walk-through weapons detection systems. Its flagship Express platform lets people keep walking, keep their bags, and skip the queue — built for what the company calls unstructured crowds: stadiums, arenas, schools, hospitals. eXpedite adds AI bag screening for high-clutter environments, and Evolv Insights layers analytics on top. It's a small company with very large logos and a product that solves a real operational headache. The technology is not the problem here.

The operating trend is genuinely improving

The financial arc is what you want to see from an early-stage compounder. Revenue climbed from $80.4M in FY2023 to $103.9M in FY2024 and $145.9M in FY2025, with gross margin expanding to roughly 50% on a trailing basis. Net losses narrowed sharply — from -$106.3M in FY2023 to -$54.0M in FY2024 to -$33.1M in FY2025.

The cash flow story matters more. Operating cash flow swung to positive $18.7M in FY2025 from -$30.9M the year before. Full-year free cash flow was still negative at -$12.7M because capex ran $31.4M — so don't let anyone tell you the company was free-cash-flow positive for the year. But Q3 2026 delivered positive free cash flow of $3.2M and a 10% adjusted EBITDA margin. Thin, new, one quarter — but the first real evidence the model can produce cash rather than just consume it.

Recurring revenue supports the case: Q3 2026 ARR reached a record $32.5M, about 69% of total revenue, with 108% net revenue retention, while remaining performance obligations of $326M grew 12% year over year. Management guides 20%+ revenue growth for 2027 and roughly 25% CAGR through 2031.

Where the growth rate gets misread

Q3 2026 revenue grew 10% year over year — a deceleration from the 34% posted in Q2. That looks alarming in isolation, but the comparison was against a tough prior-year large contract. The underlying trend is stronger than the headline rate suggests. Investors should also weigh the planned shift from upfront product sales to subscription pricing, which management expects to create a 3–4% revenue growth headwind in 2027 while improving revenue quality and durability. A slower reported growth rate alongside rising ARR is a feature of that transition, not necessarily a deterioration.

The trust discount is the real story

Here is the uncomfortable part. A $15M securities class action settlement received final court approval in September 2026. That resolves one claim — but material accounting weaknesses and ongoing regulatory investigations remain unresolved. A director also sold 80,745 shares (~$480K) in July 2026, a modest signal the market nonetheless reads.

This is why EVLV diverges so violently from its industry. A beta of 1.82 amplifies swings in both directions, but high beta doesn't make a stock fall 40% while peers rise 44%. That gap is company-specific, and it is about credibility rather than demand. The question worth sitting with: can a company grow its way out of an accounting problem? Sometimes yes — if controls get fixed and growth is real, the discount fades. Sometimes no, because trust is expensive to rebuild.

What the price is actually paying for

At $3.90, EVLV trades at roughly 4.0x trailing sales, with a $707M market cap and $687M enterprise value. There is no meaningful P/E because there are no earnings — consensus EPS estimates remain negative through FY2028 (-$0.12, -$0.08, -$0.10). Return on equity is -16.3% and ROIC is -23.7%, so the business does not yet earn its cost of capital. TTM free cash flow yield is just 1.2%.

That means the price is a bet on the future, not a reflection of the present. A third-party DCF/APV estimate puts fair value at $6.59, suggesting upside if execution holds — but sensitivity to assumptions is high, and that figure should be treated as one input, not a verdict.

The balance sheet and the risks that matter

Leverage is manageable: debt-to-equity of 0.38, a current ratio of 1.09, and $49.2M in cash at FY2025 year-end. That is a cushion, not over-capitalization.

The threats are concrete. Legal and regulatory overhang persists beyond the settled claim. The 2027 pricing transition, international compliance investment (non-US revenue was only $5.3M of FY2025's $145.9M), and reliance on sales capacity expansion all create execution risk against the 20%+ growth target. Gross margin is compressed by mix shift toward purchase subscriptions and Gen2 upgrades, with price increases and manufacturing changes intended as offsets but not yet fully materialized. And competitive pressure in security technology demands continued AI and product spending.

The balanced read

EVLV presents a genuine tension: an improving operating business — record revenue, positive operating cash flow, a $326M backlog, 108% net revenue retention — priced at a deep discount because governance and control concerns have damaged credibility. The bull case rests on remediation progress and durable ARR growth; the bear case rests on unresolved investigations and the possibility that trust, once broken, stays expensive. Neither outcome is predetermined. For long-term investors, the key monitoring points are internal control remediation, the pace of the 2027 pricing transition, and whether free cash flow builds on Q3's first positive quarter.

Explore on MarketSnap

– [Evolv Technologies stock page](https://marketsnap.com/EVLV/) — current price, valuation multiples, and key financials in one view.
– [EVLV Intrinsic Value Calculator](https://marketsnap.com/intrinsic-value/evlv/) — see the assumptions behind a fair-value estimate for an unprofitable growth company.
– [Evolv Investment Outlook](https://marketsnap.com/EVLV/outlook/) — how the growth, margin, and trust questions frame the forward case.
– [Build your EVLV investment case](https://marketsnap.com/EVLV/investment-case/) — a structured workflow for weighing the evidence yourself.